ArticleBlood advances2019

Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia.

Elisavet Chartomatsidou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.